Delivery Order SPE2DB24D1104-SPE2DB25FYEQ5
- Not listed
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,492.56 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by September 9, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,033.29 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $8,001.71. This is a firm fixed price, non-competitive delivery order executed under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The order will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $5,996.73 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on August 14, 2025, with an ultimate completion date of August 15, 2025. The contract does not include a set-aside designation. Performance will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $5,177.14 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on August 26, 2025, with an ultimate completion date of August 27, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified vendors. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,347.84 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of September 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,425.07 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply). This competitively awarded, firm fixed-price delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025, and represents a non-set-aside procurement. The work is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $11,073.06 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a contract ceiling value of $3,874.25. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYEQ5Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,579.01 to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count units) with an ultimate completion date of August 15, 2025. This firm fixed-price delivery order, awarded on August 14, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceutical products and medical supplies across multiple therapeutic domains to support military healthcare programs. The ondansetron supply fulfills the Defense Health Agency's ongoing medical procurement needs, with the company competing successfully against other potential vendors to deliver this essential anti-nausea medication supporting federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.6k | 8/14/25 |